



Predicted Impact of Variants on Abbott SARS-CoV-2/COVID-19 Diagnostic Tests

TECHNICAL BRIEF

August 30th, 2021

Purpose: This Technical Brief is an up-to-date overview on the predicted impact, if any, to the performance of Abbott SARS-CoV-2/COVID-19 diagnostic tests in the detection of SARS-CoV-2 viral variants, as determined through ongoing analysis by the Abbott Pandemic Defense Coalition. This document is provided as assurance to customers that Abbott is conducting continuous and thorough analysis of emerging SARS-CoV-2 variants.

Background: Emerging variants of the SARS-CoV-2 virus have been identified across the globe with concerning pathogenic properties.^{1,2} Assessing the risk emerging variants may pose to public health relies on continued identification and characterization.³ Concerns have been raised as some variants have been reported to have increased viral transmission and disease severity.⁴ As these variants are identified, it is imperative that efforts are taken to monitor any potential impact the genomic mutations have on viral detection by Abbott diagnostic tests.

Abbott Monitoring: Abbott is continuously monitoring the global SARS-CoV-2 situation through complex processes overseen by the Abbott Pandemic Defense Coalition.^{5,6} As emerging variants are identified, sequence and *in silico* analyses are conducted to evaluate potential impact of these mutations to our tests. This proactive monitoring scheme enables Abbott to communicate the most up to date information specific to our tests. While the detailed evidence is proprietary, Abbott recognizes the need to provide customer assurance on our test performance. In addition to this document, the Abbott Pandemic Defense Coalition has published a study evaluating the Abbott molecular, antigen, and serologic assays with several SARS-CoV-2 viral variants and will continue to publish as evaluations of emerging variants continue to arise.⁶

Predicted Impact of Variants on Abbott SARS-CoV-2/COVID-19 Diagnostic Tests:

The following table lists the Abbott SARS-CoV-2/COVID-19 diagnostic tests, the target(s) detected, and any predicted impact on assay performance based on data analyses to date (see **Table 2, Summary of Variants Analyzed to Date**).

Table 1: Predicted Impact of Variants on Abbott SARS-CoV-2/COVID-19 Diagnostic Tests:

Abbott SARS-CoV-2/COVID-19 Test	Detected Target(s)	Test Performance
Panbio™ COVID-19 Ag Rapid Test Device	N* protein	No Predicted Impact
Panbio™ COVID-19 Antigen Self-Test	N protein	No Predicted Impact
Panbio™ COVID-19 IgG/IgM Rapid Test Device	N protein	No Predicted Impact
BinaxNOW™ COVID-19 Ag Card	N protein	No Predicted Impact
BinaxNOW™ COVID-19 Antigen Self Test	N protein	No Predicted Impact
ID NOW™ COVID-19 Test	RdRp** gene	No Predicted Impact
Alinity m SARS-CoV-2	RdRp and N genes	No Predicted Impact
Alinity m Respiratory-4-Plex	RdRp and N genes	No Predicted Impact
RealTime SARS-CoV-2	RdRp and N genes	No Predicted Impact

*N – Nucleocapsid; **RdRp – RNA dependent RNA polymerase

Table 2: Summary of Variants Analyzed to Date:^{2-4,6,7,8, 9}

WHO Nomenclature	Lineage	Country First Detected	Additional Nomenclature
Alpha	B.1.1.7	England, UK	VOC-202012/01, VOC-20DEC-01, VUI-202012/01; VUI-202012/01; Clade GR; 20I/501Y.V1
Beta	B.1.351	South Africa	VOC-202012/02, VOC-20DEC-02, 20H/501Y.V2, 501Y.V2, Clade GH/501Y.V1
Beta	B.1.351.2	South Africa	Clade GH/501Y.V2; 20H(V2)/S:L18F
Beta	B.1.351.3	South Africa	Clade GH/501Y.V2; 20H(V2)/S:L18F
Gamma	P.1	Japan ex Manaus, Brazil	B.1.1.28.1, VOC-202101/02, VOC-21JAN-02, 20J/501Y.V3
Gamma	P.1.1	Brazil	G/478K.V1, 21A
Gamma	P.1.2	Brazil	G/478K.V1, 21A
Delta*	B.1.617.2	India	VOC-21APR-02; 20A/S:478K
Delta*	AY.1	India	Delta Plus
Delta*	AY.2	India	Clade G/478K.V1; 21A/S:417N
Delta*	AY.3	India	Clade G/478K.V1; 21A/S:417N
Delta*	AY.3.1	USA	None to date
Delta*	AY.4	Not confirmed	None to date

Delta*	AY.5	Not confirmed	None to date
Delta*	AY.6	Thailand	None to date
Delta*	AY.7	India	None to date
Delta*	AY.8	Not confirmed	None to date
Delta*	AY.9	India	None to date
Delta*	AY.10	Not confirmed	None to date
Delta*	AY.11	Not confirmed	None to date
Delta*	AY.12	Not confirmed	None to date
Epsilon	B.1.427	California, USA	20C/S:452R; Clade GH/452R.V1; CAL.20C/L452R
Epsilon	B.1.429	California, USA	20C/S:452R; Clade GH/452R.V1; CAL.20C/L452R
Zeta	P.2	Brazil	VUI-202101/01, VUI-21JAN-01, 20J
Eta	B.1.525	England, UK, Nigeria	VUI-21FEB-03, VUI-202102/03; 20A/S:484K; Clade G/484K.V3
Theta	P.3	Philippines	VUI-21MAR-02
Iota	B.1.526	New York, USA	20C/s:484k; Clade GH
Kappa	B.1.617.1	India	VUI-21APR-01; 20A/S:154K
Lambda	C.37	Peru	20D, GR/452Q.V1
Mu	B.1.621	Colombia	Clade GH, 21H
Mu	B.1.621.1	Not confirmed	None to date
Not designated	A.23.1+E484K	England, UK	VUI-21FEB-01, VUI-202102/01
Not designated	A.27	Not confirmed	None to date
Not designated	AT.1	Russia	VUI-21MAY-01
Not designated	AV.1	England, UK	VUI-21MAY-01
Not designated	B.1.1.318	England, UK	VUI-21FEB-04, VUI-202102/04
Not designated	B.1.1.519	Mexico	Clade GR; 20B/S.732A
Not designated	B.1.1.523	Not confirmed	Clade GR
Not designated	B.1.1.7 with E484K	England, UK	VOC-21FEB-02; VOC-202102/02

Not designated	B.1.214.2	Not confirmed	Clade G
Not designated	B.1.429.1	Not confirmed	None to date
Not designated	B.1.466.2	Indonesia	Clade GH
Not designated	B.1.526.1	New York, USA	20C
Not designated	B.1.526.2	New York, USA	None to date
Not designated	B.1.616	France	20C; Clade GH
Not designated	B.1.617.3	India	VUI-21APR-03; 20A
Not designated	B.1.618	India	None to date
Not designated	B.1.619	Not confirmed	Clade G, 20A/S.126A
Not designated	B.1.620	Not confirmed	Clade G
Not designated	B.1.628	Not confirmed	None to date
Not designated	C.1.2	South Africa	Clade GR
Not designated	C.36.3	Not confirmed	Clade GR; 20D
Not designated	C.36.3.1	Not confirmed	Clade GR; 20D
Not designated	R.1	Japan and USA	Clade GR

* Includes all AY lineages, which as noted by the WHO, is an alias for B.1.617.2 in Pango nomenclature.^{9,10}

Technical Support:

If you have any questions on the provided information or are able to provide access to emerging variant samples, please contact Technical Support.

ID NOW™ COVID-19 test^: <https://www.globalpointofcare.abbott/en/product-details/id-now-covid-19.html>

BinaxNOW™ COVID-19 Ag Card^:

Professional: <https://www.globalpointofcare.abbott/en/product-details/navica-binaxnow-covid-19-us.html>

Proctored: <https://www.globalpointofcare.abbott/en/product-details/binaxnow-covid-19-home-test-us.html>

BinaxNOW™ COVID-19 Self Test:

<https://www.globalpointofcare.abbott/en/product-details/binaxnow-covid-19-antigen-self-test-us.html>

Panbio™ COVID-19 Ag Rapid Test Device#:

<https://www.globalpointofcare.abbott/en/product-details/panbio-covid-19-ag-antigen-test.html>

Panbio™ COVID-19 IgG/IgM Rapid Test Device#:

<https://www.globalpointofcare.abbott/en/product-details/panbio-covid-19-igg-igm-antibody-test.html>

Panbio™ COVID-19 Antigen Self-Test#:

<https://www.globalpointofcare.abbott/en/product-details/panbio-covid-19-antigen-self-test.html>

Abbott Alinity m SARS-CoV-2[^], Alinity m Respiratory-4-Plex[^], RealTime SARS-CoV-2[^]:

Global: <https://www.molecular.abbott/int/en/contact-technical-support>

US: <https://www.molecular.abbott/us/en/knowledge-center/support>

¹ www.cdc.gov/coronavirus/2019-ncov/transmission/variant.html (Accessed 09/14/2021)

² <https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-cases-data> (Accessed 09/14/2021)

³ <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html> (Accessed 09/14/2021)

⁴ <https://www.ecdc.europa.eu/en/covid-19/variants-concern> (Accessed 09/14/2021)

⁵ <https://www.abbott.com/corpnewsroom/products-and-innovation/how-we-track-covid-19-variants.html> (Accessed 09/14/2021)

⁶ <https://doi.org/10.1101/2021.04.24.21256045> (Accessed 09/14/2021)

⁷ Abbott data on file

⁸ <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports> (Accessed 09/14/2021)

⁹ <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/> (Accessed 09/14/2021)

¹⁰ <http://pango.network/new-ay-lineages/> (Accessed 09/14/2021)

FOR EXTERNAL USE

Products not available in all countries. Available to consumers in select markets.

#The Panbio™ COVID-19 Ag Rapid Test Device, Panbio™ COVID-19 IgG/IgM Rapid Test Device, and Panbio™ COVID-19 Antigen Self-Test are not available for sale in US.

[^] Emergency Use Authorization (EUA) Conditions for BinaxNOW™ COVID-19 Ag Card, BinaxNOW™ COVID-19 Antigen Self Test, ID NOW™ COVID-19, Alinity m SARS-CoV-2, Alinity m Resp-4-Plex and RealTime SARS-CoV-2 assay:

- BinaxNOW™ COVID-19 Ag Card has not been FDA cleared or approved, but have been authorized for emergency use by FDA under an EUA. It has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens;
- The BinaxNOW™ COVID-19 Antigen Self Test has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization. It has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. BinaxNOW COVID-19 Antigen Self Test should be performed twice in 3 days, at least 36 hours apart;
- ID NOW™ COVID-19 has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories or patient care settings;
- Alinity m SARS-CoV-2, Alinity m Resp-4-Plex and RealTime SARS-CoV-2 assays have not been FDA cleared or approved, but have been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
- ID NOW™ COVID-19, Alinity m SARS-CoV-2 assay and RealTime SARS-CoV-2 assay have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens;
- Alinity m Resp-4-Plex has been authorized only for the detection and differentiation of nucleic acid from SARS-CoV-2, influenza A, influenza B, and/or Respiratory Syncytial Virus, not for any other viruses or pathogens;
- The emergency use of the products are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of *in vitro* diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

© 2021 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners.